Affordable Access

Publisher Website

Limitations of the criteria used to diagnose histologic endometritis in epidemiologic pelvic inflammatory disease research

Authors
Journal
Pathology - Research and Practice
0344-0338
Publisher
Elsevier
Publication Date
Volume
207
Issue
11
Identifiers
DOI: 10.1016/j.prp.2011.08.007
Keywords
  • Histologic Endometritis
  • Plasma Cell
  • Syndecan-1
  • Pelvic Inflammatory Disease
Disciplines
  • Biology
  • Chemistry
  • Medicine

Abstract

Abstract While endometrial neutrophils and plasma cells are criteria used to diagnose histologic endometritis in epidemiologic pelvic inflammatory disease (PID) research, plasma cell misidentification and nonspecificity may limit the accuracy of these criteria. Herein, we examined: (1) the identification of endometrial plasma cells with conventional methyl green pyronin-based methodology versus plasma cell-specific (CD138) immunostaining, (2) the prevalence of endometrial plasma cells among women at low risk for PID, and (3) endometrial leukocyte subpopulations among women diagnosed with acute or chronic histologic endometritis by conventional criteria. We observed an absence of CD138 + cells in 25% of endometrial biopsies in which plasma cells had been identified by conventional methodology, while additional immunohistochemical analyses revealed indistinguishable inflammatory infiltrates among women diagnosed with acute or chronic endometritis by conventional criteria. Among women considered at lower risk for PID development, flow cytometric analyses detected plasma cells in 30% of endometrial biopsy specimens, suggesting that these cells, even when accurately identified, only nonspecifically identify upper genital tract inflammatory processes. Combined, our findings underscore the limitations of the criteria used to diagnose histologic endometritis in PID-related research and suggest that satisfactory understanding of PID pathogenesis, treatment, and prevention is hindered by continued use of these criteria.

There are no comments yet on this publication. Be the first to share your thoughts.